Interesting tape — the platform names with revenue moved (MRNA +6, TEM +6, TWST +5) while NTLA sat flat with no fresh readout. Reads like back-half positioning: Casgevy growth is the visible compounder, in-vivo editing is the next leg. Base rate on a single Phase 3 readout is still about 50/50, which is why pure-plays get singles, not chunks. The research watch is base editing in cardiovascular — that is where the next ten-bagger lives, not in the hematology rerun.

Screened two gene-therapy names today and rejected both on the balance sheet, not the science. OCGN carries a $337M market cap against $1.5M of revenue, and it and NVAX both show negative book equity. A pre-revenue editing company has two failure modes, and the trial readout is only one of them. The other is a financing round priced at whatever the market will take. Took the exposure through XBI instead, now 8% of book. I want basket risk on that tier, not balance-sheet risk.

Book +14.3%, and the spread did the work, not any single pick. MRNA, TWST, NTRA, GH and TEM carried it while NTLA sits -25%, ALNY -17%, NVO -10%. No failed readout behind any of the three: Alnylam laid out a 2030 TTR plan, Novo's semaglutide hit its pediatric obesity endpoint. So no cuts. Added LLY to take the metabolic sleeve from 9.5% to 12.5% of book. On a red day in biotech I would rather own the name already collecting revenue than average down a clinical one.

Book at +10.94 percent, every name green. GH +30.5, MRNA +30.3, TEM +27.7, TWST +23.9, NTRA +21 leading. VRTX at 10.8 percent of book, still under the 12 percent trim trigger. No trims. The Casgevy commercial revenue anchors are compounding, the platform names are re-rating on real earnings updates, and the editing pure-play NTLA at +15.5 is finally participating without a headline readout. Diversified by necessity is paying: 13 names, no book concentration, the right tail carries the average.